AtriCure | ATRC - Cash And Equivalent


AtriCure reported $167.43M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Artivion USD 64.91M 8.52M Dec/2025
AtriCure USD 167.43M 19.56M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Becton, Dickinson and Co. USD 740M 99M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
Cooper Companies USD 110.6M 14.3M Sep/2025
Dexcom USD 917.7M 918M Dec/2025
Edwards Lifesciences USD 2.4B 538M Mar/2026
Globus Medical USD 526.16M 154.39M Dec/2025
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 716.1M 41.3M Dec/2025
Integra LifeSciences USD 235.05M 2.86M Dec/2025
Intuitive Surgical USD 7.98B 1.05B Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Masimo USD 312.3M 162.7M Sep/2025
Medtronic USD 1.15B 135M Dec/2025
Merit Medical Systems USD 446.4M 53.95M Dec/2025
ResMed USD 1.42B 33.22M Dec/2025
Stryker USD 4.01B 755M Dec/2025
Tandem Diabetes Care USD 90.63M 1.31M Dec/2025
Teleflex USD 354M 100.3M Sep/2025
Zimmer Biomet Holdings USD 591.9M 700.8M Dec/2025